News & Events about Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as ...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the...
Ticker Report
3 months ago
Akero Therapeutics, Inc. (NASDAQ:AKRO Get Rating) Director Seth Loring Harrison sold 4,515 shares of the businesss stock in a transaction dated Tuesday, October 25th. The shares were sold at an average price of $44.92, for a total value of $202,813.80. Following the completion of the ...
Ticker Report
4 months ago
Akero Therapeutics, Inc. (NASDAQ:AKRO Get Rating) insider Timothy Rolph sold 45,000 shares of the companys stock in a transaction on Friday, September 30th. The stock was sold at an average price of $32.72, for a total value of $1,472,400.00. Following the transaction, the insider now...